Active-ingredient Dossier

["budesonide"

Active-ingredient Dossier for ["budesonide" (inhaled corticosteroid). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.

Brand: BUDEFLO
Therapeutic area: Respiratory

What is

Budesonide Budesonide is an inhaled corticosteroid.

Australian brands containing

Budesonide — BUDENOFALK — ENTOCORT — JORVEZA — PULMICORT — RHINOCORT — BUFOMIX EASYHALER — BREZTRI AEROSPHERE — SYMBICORT — DUORESP SPIROMAX — CORTIMENT — BUDAMAX AQUEOUS NASAL SPRAY — RILAST

Therapeutic areas

Budesonide is registered in respiratory (11 brands), immunology (3 brands), gastroenterology (3 brands), and complementary medicine (1 brand).

Sponsor landscape

The ingredient is marketed by AstraZeneca, Johnson & Johnson, Cipla, Dr Falk Pharma, Mayne Pharma, and Alphapharm.

PBS and regulatory activity

Four brands containing budesonide have PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2022–23 financial year, government expenditure on budesonide-containing brands was $75.3 million across 2.2 million scripts. The latest PBAC outcome for budesonide brands was recorded on 1 November 2024, with 10 brands holding PBAC outcomes on record. The latest AusPAR was issued on 16 July 2021, with 3 brands holding AusPARs on record.